​Dr Cao Taige, Consultant, Dermatology Service, SKH, shared that Eczema is a common health issue locally, affecting about 20% of children and 10% of adults. Most patients have mild symptoms that can be effectively controlled with regular use of moisturisers and gentle, fragrance-free body washes. Mild flare-ups can usually be alleviated within one to two weeks with the application of topical steroid creams. Patients with frequent or persistent widespread flare-ups may have moderate to severe eczema, and topical medications alone often fail to provide adequate control.

Dr Cao emphasised that patients with moderate to severe eczema not only endure physical suffering but also face social, psychological, and economic pressures. Incidence of anxiety and depression in these patients can be as high as 20%. For the past 30 to 40 years, ultraviolet therapy and traditional immunosuppressants were the main treatment methods. However, with a deeper understanding of the condition and technological advancements, two new categories of drugs have currently shown exceptional efficacy in treatment: JAK inhibitors, such as Abrocitinib, recently included under the Ministry of Health's Medication Assistance Fund, and targeted biological therapies like Dupilumab. Compared to traditional treatments, these new drugs are not only more effective but also safer. Dr Cao pointed out that while these drugs could have some side effects and may not suitable for everyone, they can be used safely under the strict supervision of dermatologists.